Dr. Valente is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1800 Lorain Ave
Cleveland, OH 44113Phone+1 216-252-2235Fax+1 216-445-4048
Summary
- Dr. Stephanie Valente is the Director of the Cleveland Clinic West Region Breast Program. She serves at the Medical Director of the Fairview Hospital Breast Program in Cleveland, OH and is the Breast Surgery Fellowship Program Director. She is a Breast Surgical Oncologist and Associate Professor of Surgery. She specializes in breast cancer surgery and advanced surgical techniques.
Education & Training
- U Southern California2011
- Summa Health System/NEOMEDResidency, Surgery, 2005 - 2010
- Summa Health System/NEOMEDInternship, Surgery, 2005 - 2006
- Ohio University Heritage College of Osteopathic Medicine in AthensClass of 2005
Certifications & Licensure
- OH State License 2005 - 2025
- CA State License 2010 - 2012
- American Board of Surgery Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow American College of Surgeons
Clinical Trials
- Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery Start of enrollment: 2012 May 18
Publications & Presentations
PubMed
- 5 citationsReducing rates of chronic breast cancer-related lymphedema with screening and early intervention: an update of recent data.Pat Whitworth, Frank Vicini, Stephanie A Valente, Kirstyn Brownson, Beth DuPree
Journal of Cancer Survivorship. 2024-04-01 - 8 citationsThe Landmark Series: Adjuvant Radiation Therapy for Breast Cancer.Stephanie A. Valente, Chirag Shah
Annals of Surgical Oncology. 2020-04-20 - 16 citationsRetrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.Shruti Rakesh Tiwari, Prasun J. Mishra, Paola Raska, Benjamin C. Calhoun, Jame Abraham
Breast Cancer Research and Treatment. 2016-06-20
Journal Articles
- Triple Mapping to Optimize Axillary Management in Breast Cancer Patients After Neoadjuvant TherapyRisal Djohan, Stephanie Valente, Graham Schwarz, Stephen Grobmyer, Sabrina Shilad, Annals of Surgical Oncology
- Outcomes of Autologous Fat Grafting in Mastectomy Patients Following Breast ReconstructionSteven L Bernard, Stephanie A Valente, Stephen R Grobmyer, Annals of Surgical Oncology
Press Mentions
- Breast Surgery and Opioids: What You Need to KnowNovember 4th, 2021
- Regional Anesthesia for the Practicing, General SurgeonOctober 25th, 2021
- Breast Cancer Treatment Option Works for SomeOctober 17th, 2018
Professional Memberships
- Fellow
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: